The public FDA record ties this applicant to a single documented submission in the supplied filings: K262208, received 30 June 2026 and decided 1 October 2026 as substantially equivalent under the traditional review track, with a summary statement on file. The device is classified under 21 CFR 880.6250 as a non-powdered patient examination glove, Class I, product code LZA, with the review panel listed as General Hospital. The filing address is in Sitiawan, Perak, Malaysia; that address is a correspondence location in the filing and is not treated here as a verified headquarters. [1][2][3][4]

The cleared device and its stated scope

K262208 covers three named glove configurations: non-sterile, powder-free nitrile examination aloe vera green gloves with low dermatitis potential, tested for use with chemotherapy drugs, fentanyl citrate and simulated gastric acid; a blue version carrying the same description; and non-sterile, powder-free nitrile examination gloves in pink. The device name itself carries the testing claims, so the scope of the clearance is defined by those product identities rather than by any performance figure. [1][3][4]

The regulation cited is 21 CFR 880.6250, non-powdered patient examination glove, with device class I and product code LZA. The advisory committee and review panel are both recorded as General Hospital, and the clearance type is traditional with no third-party review flag. [1][3][4]

Submission timeline and review path

The application was received on 30 June 2026 and decided on 1 October 2026, a decision code of SESE, described as substantially equivalent. The record notes a summary statement, and the FDA database entry for the same 510(k) number shows a page last updated 26 October 2026. [1][2][4]

The supplied collection for this applicant contains one linked 510(k) record, and that single record carries a SESE decision; the sample decision count matches the full collection count because the collection itself holds one entry. These figures describe the supplied filings as of the snapshot date and are not a measure of total clearances, sales or safety performance. [1]

Applicant identity and address in the filing

The applicant name on the submission is Yty Industry (Manjung) Sdn Bhd, with a contact listed as Punitha Samy and an address at Lot 1422-1424, Batu 10 Lekir, Sitiawan, postal code 32020, country code MY. A separate document in the filing set carries letterhead for YTY Industry Sdn. Bhd. at the same Lot 1422-1424, Batu 10 Lekir, Sitiawan, Perak address, with telephone and fax numbers and a ytygroup.com.my domain. [1][3]

The letterhead entity and the FDA applicant are not identical names, and the public documents do not establish a parent, subsidiary or brand relationship between them beyond the shared address and the YTY naming. Any ownership structure, corporate website for the applicant itself, or manufacturing site designation remains unknown from these documents. [1][3]

How the record compares with other glove filings

Other 510(k) records in the public documentation show the same regulatory frame for nitrile examination gloves: K230681 and K230875, both cleared in 2023 to Central Medicare Sdn. Bhd. of Teluk Intan, Perak, cite 21 CFR 880.6250, Class I, and product codes LZA, LZC, OPJ and QDO, with chemotherapy drug, gastric acid and fentanyl permeation resistance claims. Those clearances belong to a different applicant and are useful only as context for the product category. [6][9]

A separate FDA database page for K202536 lists product code LZA with subsequent code LZC, regulation 880.6250, a General Hospital panel, a traditional review and a substantially equivalent decision, illustrating how the agency's public entries present comparable glove submissions. A third-party index also lists a 2026 clearance to Kossan International Sdn Bhd for dual-color nitrile examination gloves with chemotherapy drug, fentanyl citrate, xylazine HCl and simulated gastric acid testing claims. [4][8]